Aquatic Capital Management’s Cytokinetics CYTK Stock Holding History

Aquatic Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10.7M	Buy	125,090 +52,612	+73%	+$3.78M	0.37%	58
2026 Q1	$4.78M	Sell	72,478 -25,019	-26%	-$1.59M	0.14%	199
2025 Q4	$6.19M	Sell	97,497 -38,372	-28%	-$2.39M	0.18%	140
2025 Q3	$7.47M	Buy	135,869 +130,372	+2,372%	+$5.37M	0.14%	180
2025 Q2	$182K	Sell	5,497 -69,336	-93%	-$2.41M	﹤0.01%	1030
2025 Q1	$3.01M	Sell	74,833 -100,720	-57%	-$4.63M	0.08%	322
2024 Q4	$8.26M	Buy	175,553 +99,653	+131%	+$5.18M	0.22%	116
2024 Q3	$4.01M	Buy	75,900 +70,300	+1,255%	+$3.92M	0.1%	225
2024 Q2	$303K	Buy	+5,600	New	+$338K	0.01%	646
2023 Q3	–	Sell	-3,900	Closed	-$127K	–	1322
2023 Q2	$127K	Buy	+3,900	New	+$144K	0.01%	786

Other funds holding CYTK

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aquatic Capital Management's CYTK Position: Q2 2026 in Review

Aquatic Capital Management increased its Cytokinetics (CYTK) stake by 73% in Q2 2026, buying an estimated $3.78M and bringing the position to 125,090 shares worth $10.7M. The position accounts for 0.37% of the portfolio, ranked #58.

Aquatic Capital Management first reported a position in CYTK in Q2 2023 and has held it in 10 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

Aquatic Capital Management held 125,090 shares of Cytokinetics worth $10.7M as of Q2 2026.
Aquatic Capital Management bought 52,612 Cytokinetics shares in Q2 2026, an estimated $3.78M.
Cytokinetics made up 0.37% of Aquatic Capital Management's portfolio in Q2 2026, its #58 holding.
Aquatic Capital Management first reported a position in Cytokinetics in Q2 2023 and has held it in 10 quarters since.
482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Aquatic Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.